- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
1. | Registration Statements (Form S-3 Nos. 333-276856, 333-252078, 333-252903, 333-257433, 333-257661 and Form S-1 No. 333-250945) of Zevra Therapeutics, Inc., |
2. | Registration Statements (Form S-8 Nos. 333-203703) pertaining to the Incentive Stock Plan, as amended, and the 2014 Equity Incentive Plan of Zevra Therapeutics, Inc., |
3. | Registration Statements (Form S-8 Nos. 333-210369, 333-216858, 333-224062, 333-230041, 333-236794, 333-252743, and 333-270340) pertaining to the 2014 Equity Incentive Plan of Zevra Therapeutics, Inc., and |
4. | Registration Statements (Form S-8 Nos. 333-257429 and 333-270340) pertaining to the Amended and Restated 2014 Equity Incentive Plan, and the 2021 Employee Stock Purchase Plan of Zevra Therapeutics, Inc.; |
5. | Registration Statement (Form S-8 No. 333-270341) pertaining to the 2023 Employment Inducement Award Plan of Zevra Therapeutics, Inc.; |
of our report dated April 1, 2024, with respect to the financial statements of Zevra Therapeutics, Inc. included in this Annual Report (Form 10-K) of Zevra Therapeutics, Inc. for the years ended December 31, 2023, and 2022.
/s/ Ernst & Young LLP
Orlando, Florida
April 1, 2024